Skip to main content
SpringerLink
Log in

Autistische Störungen (Tief greifende Entwicklungsstörungen, ICD-10 F84)

  • Chapter
Neuro-Psychopharmaka im Kindes- und Jugendalter

Zusammenfassung

Frühkindlicher Autismus (F84.0) ist eine tief greifende Entwicklungsstörung mit Beginn vor dem dritten Lebensjahr und lebenslanger Persistenz. Symptome sind

  • Auffälligkeiten im sozialen Kontaktverhalten (Desinteresse und Unfähigkeit bezüglich Kontaktaufnahme, kommunikative Defizite, Mangel an sozio-emotionaler Gegenseitigkeit);

  • reduziertes oder fehlendes Sprachvermögen, Mangel nonverbaler kommunikativer Fähigkeiten;

  • repetitive und stereotype Verhaltensmuster sowie

  • Sonderinteressen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  • Aman MG, Langworthy KS (2000) Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 30: 451–459

    Article  PubMed  CAS  Google Scholar 

  • Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y, (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adol Psychiatry 45: 1196–1205

    Article  Google Scholar 

  • Arnsten AF, Steere JC, Hunt RD (1996) The contribution of alpha2-noradrenergic mechanisms of prefrontal cortical cognitive function: potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53: 448–455

    PubMed  CAS  Google Scholar 

  • Baghdadli A, Gonnier V, Aussilloux C (2002) Review of psychopharmacological treatments in adolescents and adults with autistic disorders. Encéphale-Rev Psychiatr Clin Biol Ther 28: 248–254

    CAS  Google Scholar 

  • Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmermann AJ (2001) Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31: 175–181

    Article  PubMed  CAS  Google Scholar 

  • Buitelaar JK, Willemsen-Swinkels SHN (2000) Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9: I/85–I/97

    Article  Google Scholar 

  • Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL (1993) A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50: 441–447

    PubMed  CAS  Google Scholar 

  • Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, Hall S, Ermer DJ, Tsai LY, Schroeder SR, Cook EH (2005) A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15: 682–692

    Article  PubMed  Google Scholar 

  • Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in hildhood and adolescent autism. Neuropsychopharmacol 30: 582–589

    Article  CAS  Google Scholar 

  • Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16: 541–548

    Article  PubMed  Google Scholar 

  • Horrigan JP, Barnhill LJ (1995) Guanfacine for the treatment of attention deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5: 215–223

    Article  Google Scholar 

  • Hunsinger DM, Nguyen T, Zebraski SE, Raffa RB (2000) Is there a basis for novel pharmacotherapy of autism? Minireview. Life Sci 67: 1667–1682

    Article  CAS  Google Scholar 

  • Hunt RD, Arnsten AFT, Asbell MD (1995) An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34: 50–54

    Article  PubMed  CAS  Google Scholar 

  • Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psyhopharmacol 12: 322–327

    CAS  Google Scholar 

  • Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22: 455–460

    Article  PubMed  CAS  Google Scholar 

  • King BH (2000) Pharmacological treatment of mood disturbances, aggression and self-injury in persons with pervasive developmental disorders. J Autism Develop Dis 30: 439–445

    Article  CAS  Google Scholar 

  • Krug DA, Arick J, Almond P (1980) Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. J Child Psychol Psychiatry 21: 221–229

    Article  PubMed  CAS  Google Scholar 

  • McDougle CJ, Kresch LE, Posey DJ (2000) Repetitive thoughts and behaviour in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30: 427–435

    Article  PubMed  CAS  Google Scholar 

  • McDougle CJ, Kem DL, Posey DJ (2002) Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41: 921–927

    Article  PubMed  Google Scholar 

  • Mihir S, Parikh BS, Kolevzon A, Hollander E (2008) Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 18: 157–178

    Article  Google Scholar 

  • Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F (2006) Risperidone improvesehavioral symptoms in childrem with autism in a randomized, double-blind, placebocontrolled trial. J Autism Dev Disord 37: 367–373

    Article  Google Scholar 

  • Parikh MS, Kolevzon A, Hollander E (2008) Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability. Child Adolesc Psychopharmacol 18: 157–178

    Article  Google Scholar 

  • Popper CW (1995) combining methylphenidate and clonidine: pharmacological questions and new reports about sudden death. J Child Adolesc Psychopharmacol 5: 157–166

    Article  Google Scholar 

  • Posey DJ, Litwiller M, Koburn A, McDougle CJ (1999) Paroxetine in autism. J Am Child Adolesc Psychiatry 38: 111–112

    Article  CAS  Google Scholar 

  • Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adoles Psychopharmacol 16: 599–610

    Article  Google Scholar 

  • Poustka F, Bölte S, Schmötzer G, Feineis-Matthews S (Hrsg) (2003) Autistische Störungen. Hogrefe, Göttingen

    Google Scholar 

  • Poustka F, Schmötzer G, Rühl D, Bölte S, Amorosa H, Rotthaus W (2007) Tief greifende Entwicklungsstörungen (F84). In: Deutsche Gesellschaft für Kinder-und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder-und Jugendpsychiatrie und Psychotherapie und Bundesverband der Ärzte für Kinder-und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes-und Jugendalter, 3. überarb. und erw. Aufl. Deutscher Ärzte-Verlag, Köln, 225–237

    Google Scholar 

  • Remington G, Sloman L, Konstantareas M, Parker K, Gow R (2001) Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 21: 440–444

    Article  PubMed  CAS  Google Scholar 

  • Remschmidt H (2008) Autismus. In: Herpertz-Dahlmann B, Resch F, Schulte-Markwort M, Warnke A (Hrsg) Entwicklungspsychiatrie. Biopsychologische Grundlagen und die Entwicklung psychischer Störungen. 2. vollst. überarb. und erw. Aufl. Schattauer, Stuttgart, 600–625

    Google Scholar 

  • Remschmidt H, Kamp-Becker S (Hrsg) (2006) Asperger-Syndrom. Springer, Heidelberg

    Google Scholar 

  • Riddle MA, Bernstein GA, Cook EH, Leonard HL, March MJS, Swanson JM (1999) Anxiolytics, adrenergic agents and naltrexone. J Am Acad Child Adolesc Psychiatry 38: 546–556

    Article  PubMed  CAS  Google Scholar 

  • Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW (1999) Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 341: 1801–1806

    Article  PubMed  CAS  Google Scholar 

  • Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatr 114: 634–641

    Article  Google Scholar 

  • Tanguay PE (2000) Pervasive developmental disorders: A 10-year review. J Am Acad Child Adolesc Psychiatry 39: 1079–1095

    Article  PubMed  CAS  Google Scholar 

  • Towbin KE (2003) Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child Adolesc Psychiatr Clin N Am 12: 23–45

    Article  PubMed  Google Scholar 

  • Unis AS, Munson JA, Rogers SJ, Goldson E, Osterling J, Gabriels R, Abbott RD, Dawson G (2002) A randomised, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry 41: 1315–1321

    Article  PubMed  Google Scholar 

  • Valicenti-McDermott MR, Demb H (2006) Clinical effects and adverse reactions of off-lable use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 16: 549–560

    Article  PubMed  Google Scholar 

  • Volkmar FR (2001) Pharmacological Interventions in autism: theoretical and practical issues. J Clin Child Psychol 30: 80–87

    Article  PubMed  CAS  Google Scholar 

  • Willemsen-Swinkels SH, Buitelaar JK, van Berckelaar-Onnes JA, van Engeland H (1999) Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label casecontrol design. J Autism Dev Disord 29: 167–169

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie, Universität Ulm, Steinhoevelstraße 5, 89075, Ulm

    Prof. Dr. C. Mehler-Wex

  2. Oberarzt der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Universität Würzburg, Füchsleinstraße 15, 97080, Würzburg

    Dr. med. J. Seifert

  3. Praxis für Kinder- und Jugendpsychiatrie und -psychotherapie Drs. Klein-Kreinkamp-Oehler, Wirsbergstraße 10, 97080, Würzburg

    Dr. med. U. Schupp

Authors
  1. Prof. Dr. C. Mehler-Wex
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. J. Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. U. Schupp
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik und Poliklinik für Kinder- und Jugendpsychiatrie, Würzburg, Deutschland

    Manfred Gerlach  & Andreas Warnke  & 

  2. Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie, Universität Ulm, Deutschland

    Claudia Mehler-Wex

  3. Kinder- und Jugendpsychiatrischer Dienst des Kantons Zürich, Zürich, Schweiz

    Susanne Walitza

  4. Kliniken der Stadt Köln, Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Köln, Deutschland

    Christoph Wewetzer

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien

About this chapter

Cite this chapter

Mehler-Wex, C., Seifert, J., Schupp, U. (2009). Autistische Störungen (Tief greifende Entwicklungsstörungen, ICD-10 F84). In: Gerlach, M., Warnke, A., Mehler-Wex, C., Walitza, S., Wewetzer, C. (eds) Neuro-Psychopharmaka im Kindes- und Jugendalter. Springer, Vienna. https://doi.org/10.1007/978-3-211-79275-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-79275-9_16

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-79274-2

  • Online ISBN: 978-3-211-79275-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation